high blood pressure and glp 1 GLP-1 has changed the conversation around weight loss—but it's important to understand what it can cannot do. It's not the right choice for everyone, and it's not a replacement for healthy Hypotension-related events increased after initiation

A recent study published in JAMA Ophthalmology reveals an elevated risk of NAION for those exposed to semaglutide

But as of 2008, the FDA discontinued its approval for GEREF for reasons other than safety or effectiveness [10]

Wegovy led to an average 21kg (46lb) loss over 72 weeks in a medical study, which equates to four dress sizes

Mounjaro (tirzepatide) is a medication that acts on both GLP-1 and GIP receptors, offering a dual mechanism to enhance weight loss and improve glucose control, making it distinct from other semaglutide treatments like ozempic for weight loss

Sudden severe mid-epigastric pain radiating to the back, especially with nausea and vomiting, is the classic presentation and warrants emergency evaluation

18, Jan